سوق علاج الخرف العالمي - اتجاهات الصناعة والتوقعات حتى عام 2029

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL DEMENTIA TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL DEMENTIA TREATMENT MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 EPIDEMIOLOGY MODELING

2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL DEMENTIA TREATMENT MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER'S 5 FORCES

4.2 PESTEL ANALYSIS

5 EPIDEMIOLOGY

5.1 INCIDENCE OF ALL BY GENDER

5.1.1 PREVALENCE OF DEMENTIA

5.2 TREATMENT RATE

5.3 MORTALITY RATE

5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

5.5 PATEINT TREATMENT SUCCESS RATES

6 INDUSTRY INSIGHTS

6.1 PATENT ANALYSIS

6.2 DRUG TREATMENT RATE BY MATURED MARKETS

6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

6.4 PATIENT FLOW DIAGRAM

6.5 KEY PRICING STRATEGIES

6.6 KEY PATIENT ENROLLMENT STRATEGIES

6.7 INTERVIEWS WITH NEUROLOGIST

6.8 INTERVIEWS WITH GENETICS SPECIALIST

6.9 OTHER KOL SNAPSHOTS

7 REGULATORY SCENARIO

7.1 FDA APPROVALS

7.2 EMA APPROVALS

8 MERGERS AND ACQUISITION

8.1 LICENSING

8.2 COMMERCIALIZATION AGREEMENTS

9 PIPELINE ANALYSIS

9.1 CLINICAL TRIALS AND PHASE ANALYSIS

9.2 DRUG THERAPY PIPELINE

9.3 PHASE III CANDIDATES

9.3.1 AGB101

9.3.1.1. ATUZAGINSTAT

9.3.1.2. AVP-786

9.3.1.3. AXS-05

9.3.1.4. AXS-05

9.3.1.5. BLARCAMESINE (ANAVEX2-73)

9.3.1.6. BREXPIPRAZOLE

9.3.1.7. DONANEMAB

9.3.1.8. ESCITALOPRAM

9.3.1.9. GANTENERUMAB

9.3.1.10. TRX0237

9.3.1.11. OTHERS

9.4 PHASE II CANDIDATES

9.4.1 ABVAC40

9.4.2 ACL-35

9.4.3 BARCITINIB

9.4.4 BAPRENEMAB

9.4.5 DAPAGLIFLOZIN

9.4.6 DARATUMUMAB

9.4.7 DRONABINOL

9.4.8 LECANEMAB

9.4.9 L-SERINE

9.4.10 LUPRON

9.4.11 OTHERS

9.5 PHASE I CANDIDATES

9.6 OTHERS (PRE-CLINICAL AND RESEARCH)

10 MARKET OVERVIEW

10.1 DRIVERS

10.2 RESTRAINS

10.3 OPPURTUNITY

10.4 CHALLENGES

11 GLOBAL DEMENTIA TREATMENT MARKET, BY TREATMENT

11.1 OVERVIEW

11.2 MEDICATION

11.2.1 CHOLINESTERASE INHIBITORS

11.2.1.1. BY DRUGS

11.2.1.1.1. DONEPEZIL

11.2.1.1.1.1 MARKET VALUE (USD MN)

11.2.1.1.1.2 MARKET VOLUME (IU)

11.2.1.1.1.3 AVERAGE SELLING PRICE (USD)

11.2.1.1.2. RIVASTIGMINE

11.2.1.1.2.1 MARKET VALUE (USD MN)

11.2.1.1.2.2 MARKET VOLUME (IU)

11.2.1.1.2.3 AVERAGE SELLING PRICE (USD)

11.2.1.1.3. GALANTAMINE

11.2.1.1.3.1 MARKET VALUE (USD MN)

11.2.1.1.3.2 MARKET VOLUME (IU)

11.2.1.1.3.3 AVERAGE SELLING PRICE (USD)

11.2.1.1.4. OTHERS

11.2.1.2. BY DRUG TYPE

11.2.1.2.1. GENERICS

11.2.1.2.2. BRANDED

11.2.1.2.2.1 ARICEPT

11.2.1.2.2.1.1. MARKET VALUE (USD MN)

11.2.1.2.2.1.2. MARKET VOLUME (IU)

11.2.1.2.2.1.3. AVERAGE SELLING PRICE (USD)

11.2.1.2.2.2 EXELON

11.2.1.2.2.2.1. MARKET VALUE (USD MN)

11.2.1.2.2.2.2. MARKET VOLUME (IU)

11.2.1.2.2.2.3. AVERAGE SELLING PRICE (USD)

11.2.1.2.2.3 RAZADYNE

11.2.1.2.2.3.1. MARKET VALUE (USD MN)

11.2.1.2.2.3.2. MARKET VOLUME (IU)

11.2.1.2.2.3.3. AVERAGE SELLING PRICE (USD)

11.2.1.2.2.4 OTHERS

11.2.2 NMDA ANTAGONIST (MEMANTINE)

11.2.2.1. MARKET VALUE (USD MN)

11.2.2.2. MARKET VOLUME (IU)

11.2.2.3. AVERAGE SELLING PRICE (USD)

11.2.3 ADUCANUMAB

11.2.3.1. MARKET VALUE (USD MN)

11.2.3.2. MARKET VOLUME (IU)

11.2.3.3. AVERAGE SELLING PRICE (USD)

11.2.4 ANXIOLYTICS

11.2.4.1. BY DRUGS

11.2.4.1.1. LORAZEPAM

11.2.4.1.1.1 MARKET VALUE (USD MN)

11.2.4.1.1.2 MARKET VOLUME (IU)

11.2.4.1.1.3 AVERAGE SELLING PRICE (USD)

11.2.4.1.2. OXAZEPAM

11.2.4.1.2.1 MARKET VALUE (USD MN)

11.2.4.1.2.2 MARKET VOLUME (IU)

11.2.4.1.2.3 AVERAGE SELLING PRICE (USD)

11.2.4.1.3. OTHERS

11.2.4.2. BY DRUG TYPE

11.2.4.2.1. GENERICS

11.2.4.2.2. BRANDED

11.2.4.2.2.1 TRAPEX

11.2.4.2.2.1.1. MARKET VALUE (USD MN)

11.2.4.2.2.1.2. MARKET VOLUME (IU)

11.2.4.2.2.1.3. AVERAGE SELLING PRICE (USD)

11.2.4.2.2.2 SERAX

11.2.4.2.2.2.1. MARKET VALUE (USD MN)

11.2.4.2.2.2.2. MARKET VOLUME (IU)

11.2.4.2.2.2.3. AVERAGE SELLING PRICE (USD)

11.2.4.2.2.3 OTHERS

11.2.5 ANTIDEPRESSANT

11.2.5.1. BY DRUGS

11.2.5.1.1. CITALOPRAM

11.2.5.1.1.1 MARKET VALUE (USD MN)

11.2.5.1.1.2 MARKET VOLUME (IU)

11.2.5.1.1.3 AVERAGE SELLING PRICE (USD)

11.2.5.1.2. PAROXETINE

11.2.5.1.2.1 MARKET VALUE (USD MN)

11.2.5.1.2.2 MARKET VOLUME (IU)

11.2.5.1.2.3 AVERAGE SELLING PRICE (USD)

11.2.5.1.3. ESCITALOPRAM

11.2.5.1.3.1 MARKET VALUE (USD MN)

11.2.5.1.3.2 MARKET VOLUME (IU)

11.2.5.1.3.3 AVERAGE SELLING PRICE (USD)

11.2.5.1.4. MIRTAZAPINE

11.2.5.1.4.1 MARKET VALUE (USD MN)

11.2.5.1.4.2 MARKET VOLUME (IU)

11.2.5.1.4.3 AVERAGE SELLING PRICE (USD)

11.2.5.1.5. TRAZODONE

11.2.5.1.5.1 MARKET VALUE (USD MN)

11.2.5.1.5.2 MARKET VOLUME (IU)

11.2.5.1.5.3 AVERAGE SELLING PRICE (USD)

11.2.5.1.6. OTHERS

11.2.5.2. BY DRUG TYPE

11.2.5.2.1. GENERICS

11.2.5.2.2. BRANDED

11.2.5.2.2.1 AKARIN

11.2.5.2.2.1.1. MARKET VALUE (USD MN)

11.2.5.2.2.1.2. MARKET VOLUME (IU)

11.2.5.2.2.1.3. AVERAGE SELLING PRICE (USD)

11.2.5.2.2.2 PAXIL

11.2.5.2.2.2.1. MARKET VALUE (USD MN)

11.2.5.2.2.2.2. MARKET VOLUME (IU)

11.2.5.2.2.2.3. AVERAGE SELLING PRICE (USD)

11.2.5.2.2.3 LEXAPRO

11.2.5.2.2.3.1. MARKET VALUE (USD MN)

11.2.5.2.2.3.2. MARKET VOLUME (IU)

11.2.5.2.2.3.3. AVERAGE SELLING PRICE (USD)

11.2.5.2.2.4 REMERON

11.2.5.2.2.4.1. MARKET VALUE (USD MN)

11.2.5.2.2.4.2. MARKET VOLUME (IU)

11.2.5.2.2.4.3. AVERAGE SELLING PRICE (USD)

11.2.5.2.2.5 DESYREL

11.2.5.2.2.5.1. MARKET VALUE (USD MN)

11.2.5.2.2.5.2. MARKET VOLUME (IU)

11.2.5.2.2.5.3. AVERAGE SELLING PRICE (USD)

11.2.5.2.2.6 OTHERS

11.2.5.3. BY DRUG TYPE

11.2.5.3.1. GENERICS

11.2.5.3.2. BRANDED

11.2.5.3.2.1 CELEXA

11.2.5.3.2.1.1. MARKET VALUE (USD MN)

11.2.5.3.2.1.2. MARKET VOLUME (IU)

11.2.5.3.2.1.3. AVERAGE SELLING PRICE (USD)

11.2.5.3.2.2 AROPAX

11.2.5.3.2.2.1. MARKET VALUE (USD MN)

11.2.5.3.2.2.2. MARKET VOLUME (IU)

11.2.5.3.2.2.3. AVERAGE SELLING PRICE (USD)

11.2.5.3.2.3 LEXAPRO

11.2.5.3.2.3.1. MARKET VALUE (USD MN)

11.2.5.3.2.3.2. MARKET VOLUME (IU)

11.2.5.3.2.3.3. AVERAGE SELLING PRICE (USD)

11.2.5.3.2.4 MIRATAZ

11.2.5.3.2.4.1. MARKET VALUE (USD MN)

11.2.5.3.2.4.2. MARKET VOLUME (IU)

11.2.5.3.2.4.3. AVERAGE SELLING PRICE (USD)

11.2.5.3.2.5 OTHERS

11.2.6 ANTIPSYCHOTIC MEDICINES

11.2.6.1. BY DRUGS

11.2.6.1.1. ARIPIPRAZOLE

11.2.6.1.1.1 MARKET VALUE (USD MN)

11.2.6.1.1.2 MARKET VOLUME (IU)

11.2.6.1.1.3 AVERAGE SELLING PRICE (USD)

11.2.6.1.2. HALOPERIDOL

11.2.6.1.2.1 MARKET VALUE (USD MN)

11.2.6.1.2.2 MARKET VOLUME (IU)

11.2.6.1.2.3 AVERAGE SELLING PRICE (USD)

11.2.6.1.3. OLANZAPINE

11.2.6.1.3.1 MARKET VALUE (USD MN)

11.2.6.1.3.2 MARKET VOLUME (IU)

11.2.6.1.3.3 AVERAGE SELLING PRICE (USD)

11.2.6.1.4. RISPERIDONE

11.2.6.1.4.1 MARKET VALUE (USD MN)

11.2.6.1.4.2 MARKET VOLUME (IU)

11.2.6.1.4.3 AVERAGE SELLING PRICE (USD)

11.2.6.1.5. OTHERS

11.2.6.2. BY DRUG TYPE

11.2.6.2.1. GENERICS

11.2.6.2.2. BRANDED

11.2.6.2.2.1 ABILIFY

11.2.6.2.2.1.1. MARKET VALUE (USD MN)

11.2.6.2.2.1.2. MARKET VOLUME (IU)

11.2.6.2.2.1.3. AVERAGE SELLING PRICE (USD)

11.2.6.2.2.2 HALODOL

11.2.6.2.2.2.1. MARKET VALUE (USD MN)

11.2.6.2.2.2.2. MARKET VOLUME (IU)

11.2.6.2.2.2.3. AVERAGE SELLING PRICE (USD)

11.2.6.2.2.3 ZYPREXA

11.2.6.2.2.3.1. MARKET VALUE (USD MN)

11.2.6.2.2.3.2. MARKET VOLUME (IU)

11.2.6.2.2.3.3. AVERAGE SELLING PRICE (USD)

11.2.6.2.2.4 RISPERDAL

11.2.6.2.2.4.1. MARKET VALUE (USD MN)

11.2.6.2.2.4.2. MARKET VOLUME (IU)

11.2.6.2.2.4.3. AVERAGE SELLING PRICE (USD)

11.2.6.2.2.5 OTHERS

11.2.7 OTHERS

11.3 THERAPY

11.3.1 COGNITIVE STIMULATION THERAPY (CST)

11.3.2 COGNITIVE REHABILITATION

11.3.3 OTHERS

12 GLOBAL DEMENTIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

12.1 OVERVIEW

12.2 ORAL

12.2.1 SOLID ORAL DRUGS

12.2.1.1. TABLETS

12.2.1.2. CAPSULES

12.2.1.3. POWDERS

12.2.1.4. PILLS

12.2.1.5. OTHERS

12.2.2 LIQUID ORAL DRUGS

12.2.2.1. SYRUPS

12.2.2.2. SOLUTIONS

12.2.2.3. OTHERS

12.2.3 SEMI-SOLID ORAL DRUGS

12.2.3.1. GELS

12.2.3.2. EMULSIONS

12.2.3.3. ELIXIRS

12.2.3.4. OTHERS

12.3 TOPICAL

12.4 PARENTERAL

12.4.1 INTRAVENOUS

12.4.2 SUBCUTANEOUS

12.4.3 OTHERS

13 GLOBAL DEMENTIA TREATMENT MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITALS

13.3 SPECIALTY CLINICS

13.4 HOME HEALTHCARE

13.5 OTHERS

14 GLOBAL DEMENTIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 HOSPITAL PHARMACY

14.3 RETAIL PHARMACY

14.4 ONLINE PHARMACY

14.5 OTHERS

15 GLOBAL DEMENTIA TREATMENT MARKET, BY GEOGRAPHY

GLOBAL DEMENTIA TREATMENT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

15.1 NORTH AMERICA

15.1.1 U.S.

15.1.1.1. U.S. DEMENTIA TREATMENT MARKET, BY TREATMENT

15.1.1.2. U.S. DEMENTIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

15.1.1.3. U.S. DEMENTIA TREATMENT MARKET, BY END USER

15.1.1.4. U.S. DEMENTIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

15.1.2 CANADA

15.1.3 MEXICO

15.1.4 DOMINICAN REPUBLIC

15.1.5 JAMAICA

15.1.6 PANAMA

15.2 EUROPE

15.2.1 GERMANY

15.2.2 FRANCE

15.2.3 U.K.

15.2.4 HUNGARY

15.2.5 LITHUANIA

15.2.6 AUSTRIA

15.2.7 IRELAND

15.2.8 NORWAY

15.2.9 POLAND

15.2.10 ITALY

15.2.11 SPAIN

15.2.12 RUSSIA

15.2.13 TURKEY

15.2.14 NETHERLANDS

15.2.15 SWITZERLAND

15.2.16 REST OF EUROPE

15.3 ASIA-PACIFIC

15.3.1 JAPAN

15.3.2 CHINA

15.3.3 TAIWAN

15.3.4 SOUTH KOREA

15.3.5 INDIA

15.3.6 AUSTRALIA

15.3.7 SINGAPORE

15.3.8 THAILAND

15.3.9 MALAYSIA

15.3.10 INDONESIA

15.3.11 PHILIPPINES

15.3.12 VIETNAM

15.3.13 REST OF ASIA-PACIFIC

15.4 SOUTH AMERICA

15.4.1 BRAZIL

15.4.2 ECUADOR

15.4.3 CHILE

15.4.4 COLOMBIA

15.4.5 VENEZUELA

15.4.6 ARGENTINA

15.4.7 PERU

15.4.8 CURAÇAO

15.4.9 PARAGUAY

15.4.10 URUGUAY

15.4.11 TRINIDAD AND TOBAGO

15.4.12 REST OF SOUTH AMERICA

15.5 MIDDLE EAST AND AFRICA

15.5.1 SOUTH AFRICA

15.5.2 SAUDI ARABIA

15.5.3 UAE

15.5.4 EGYPT

15.5.5 KUWAIT

15.5.6 ISRAEL

15.5.7 BOLIVIA

15.5.8 REST OF MIDDLE EAST AND AFRICA

15.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

16 GLOBAL DEMENTIA TREATMENT MARKET, SWOT AND DBMR ANALYSIS

17 GLOBAL DEMENTIA TREATMENT MARKET, COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: GLOBAL

17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

17.3 COMPANY SHARE ANALYSIS: EUROPE

17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

17.5 MERGERS & ACQUISITIONS

17.6 NEW PRODUCT DEVELOPMENT & APPROVALS

17.7 EXPANSIONS

17.8 REGULATORY CHANGES

17.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

18 GLOBAL DEMENTIA TREATMENT MARKET, COMPANY PROFILE

18.1 BIOGEN INC

18.1.1 COMPANY OVERVIEW

18.1.2 REVENUE ANALYSIS

18.1.3 GEOGRAPHIC PRESENCE

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENTS

18.2 EISAI CO. LTD.

18.2.1 COMPANY OVERVIEW

18.2.2 REVENUE ANALYSIS

18.2.3 GEOGRAPHIC PRESENCE

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

18.3 NOVARTIS AG

18.3.1 COMPANY OVERVIEW

18.3.2 REVENUE ANALYSIS

18.3.3 GEOGRAPHIC PRESENCE

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPEMENTS

18.4 MERZ PHARMA

18.4.1 COMPANY OVERVIEW

18.4.2 REVENUE ANALYSIS

18.4.3 GEOGRAPHIC PRESENCE

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPEMENTS

18.5 PFIZER INC.

18.5.1 COMPANY OVERVIEW

18.5.2 REVENUE ANALYSIS

18.5.3 GEOGRAPHIC PRESENCE

18.5.4 PRODUCT PORTFOLIO

18.5.5 RECENT DEVELOPEMENTS

18.6 JOHNSON & JOHNSON SERVICES

18.6.1 COMPANY OVERVIEW

18.6.2 REVENUE ANALYSIS

18.6.3 GEOGRAPHIC PRESENCE

18.6.4 PRODUCT PORTFOLIO

18.6.5 RECENT DEVELOPEMENTS

18.7 H. LUNDBECK A/S

18.7.1 COMPANY OVERVIEW

18.7.2 REVENUE ANALYSIS

18.7.3 GEOGRAPHIC PRESENCE

18.7.4 PRODUCT PORTFOLIO

18.7.5 RECENT DEVELOPEMENTS

18.8 ABBVIE INC.

18.8.1 COMPANY OVERVIEW

18.8.2 REVENUE ANALYSIS

18.8.3 GEOGRAPHIC PRESENCE

18.8.4 PRODUCT PORTFOLIO

18.8.5 RECENT DEVELOPEMENTS

18.9 ELI LILLY AND COMPANY

18.9.1 COMPANY OVERVIEW

18.9.2 REVENUE ANALYSIS

18.9.3 GEOGRAPHIC PRESENCE

18.9.4 PRODUCT PORTFOLIO

18.9.5 RECENT DEVELOPEMENTS

18.1 ABBOTT

18.10.1 COMPANY OVERVIEW

18.10.2 REVENUE ANALYSIS

18.10.3 GEOGRAPHIC PRESENCE

18.10.4 PRODUCT PORTFOLIO

18.10.5 RECENT DEVELOPEMENTS

18.11 ASTRAZENECA

18.11.1 COMPANY OVERVIEW

18.11.2 REVENUE ANALYSIS

18.11.3 GEOGRAPHIC PRESENCE

18.11.4 PRODUCT PORTFOLIO

18.11.5 RECENT DEVELOPEMENTS

18.12 TEVA PHARMACEUTICAL INDUSTRIES LTD.

18.12.1 COMPANY OVERVIEW

18.12.2 REVENUE ANALYSIS

18.12.3 GEOGRAPHIC PRESENCE

18.12.4 PRODUCT PORTFOLIO

18.12.5 RECENT DEVELOPEMENTS

18.13 F. HOFFMANN-LA ROCHE LTD.

18.13.1 COMPANY OVERVIEW

18.13.2 REVENUE ANALYSIS

18.13.3 GEOGRAPHIC PRESENCE

18.13.4 PRODUCT PORTFOLIO

18.13.5 RECENT DEVELOPEMENTS

18.14 BRISTOL-MYERS SQUIBB COMPANY

18.14.1 COMPANY OVERVIEW

18.14.2 REVENUE ANALYSIS

18.14.3 GEOGRAPHIC PRESENCE

18.14.4 PRODUCT PORTFOLIO

18.14.5 RECENT DEVELOPMENTS

18.15 ALEMBIC USA LTD

18.15.1 COMPANY OVERVIEW

18.15.2 REVENUE ANALYSIS

18.15.3 GEOGRAPHIC PRESENCE

18.15.4 PRODUCT PORTFOLIO

18.15.5 RECENT DEVELOPMENTS

18.16 APOTEX INC.

18.16.1 COMPANY OVERVIEW

18.16.2 REVENUE ANALYSIS

18.16.3 GEOGRAPHIC PRESENCE

18.16.4 PRODUCT PORTFOLIO

18.16.5 RECENT DEVELOPMENTS

18.17 WOCKHARDT

18.17.1 COMPANY OVERVIEW

18.17.2 REVENUE ANALYSIS

18.17.3 GEOGRAPHIC PRESENCE

18.17.4 PRODUCT PORTFOLIO

18.17.5 RECENT DEVELOPMENTS

18.18 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

18.18.1 COMPANY OVERVIEW

18.18.2 REVENUE ANALYSIS

18.18.3 GEOGRAPHIC PRESENCE

18.18.4 PRODUCT PORTFOLIO

18.18.5 RECENT DEVELOPMENTS

18.19 HIKMA PHARMACEUTICALS PLC

18.19.1 COMPANY OVERVIEW

18.19.2 REVENUE ANALYSIS

18.19.3 GEOGRAPHIC PRESENCE

18.19.4 PRODUCT PORTFOLIO

18.19.5 RECENT DEVELOPMENTS

18.2 VIATRIS INC.

18.20.1 COMPANY OVERVIEW

18.20.2 REVENUE ANALYSIS

18.20.3 GEOGRAPHIC PRESENCE

18.20.4 PRODUCT PORTFOLIO

18.20.5 RECENT DEVELOPMENTS

18.21 CIPLA

18.21.1 COMPANY OVERVIEW

18.21.2 REVENUE ANALYSIS

18.21.3 GEOGRAPHIC PRESENCE

18.21.4 PRODUCT PORTFOLIO

18.21.5 RECENT DEVELOPEMENTS

18.22 OTSUKA HOLDINGS

18.22.1 COMPANY OVERVIEW

18.22.2 REVENUE ANALYSIS

18.22.3 GEOGRAPHIC PRESENCE

18.22.4 PRODUCT PORTFOLIO

18.22.5 RECENT DEVELOPEMENTS

18.23 GLAXOSMITHKLINE

18.23.1 COMPANY OVERVIEW

18.23.2 REVENUE ANALYSIS

18.23.3 GEOGRAPHIC PRESENCE

18.23.4 PRODUCT PORTFOLIO

18.23.5 RECENT DEVELOPMENTS

18.24 UCB

18.24.1 COMPANY OVERVIEW

18.24.2 REVENUE ANALYSIS

18.24.3 GEOGRAPHIC PRESENCE

18.24.4 PRODUCT PORTFOLIO

18.24.5 RECENT DEVELOPEMNTS

18.25 CADILA HEALTHCARE

18.25.1 COMPANY OVERVIEW

18.25.2 REVENUE ANALYSIS

18.25.3 GEOGRAPHIC PRESENCE

18.25.4 PRODUCT PORTFOLIO

18.25.5 RECENT DEVELOPEMNTS

18.26 BAUSCH & LOMB

18.26.1 COMPANY OVERVIEW

18.26.2 REVENUE ANALYSIS

18.26.3 GEOGRAPHIC PRESENCE

18.26.4 PRODUCT PORTFOLIO

18.26.5 RECENT DEVELOPEMNTS

18.27 GRIFOLS

18.27.1 COMPANY OVERVIEW

18.27.2 REVENUE ANALYSIS

18.27.3 GEOGRAPHIC PRESENCE

18.27.4 PRODUCT PORTFOLIO

18.27.5 RECENT DEVELOPEMNTS

18.28 SINO BIOPHARMACEUTICALS

18.28.1 COMPANY OVERVIEW

18.28.2 REVENUE ANALYSIS

18.28.3 GEOGRAPHIC PRESENCE

18.28.4 PRODUCT PORTFOLIO

18.28.5 RECENT DEVELOPEMNTS

18.29 FERRING PHARMACEUTICALS

18.29.1 COMPANY OVERVIEW

18.29.2 REVENUE ANALYSIS

18.29.3 GEOGRAPHIC PRESENCE

18.29.4 PRODUCT PORTFOLIO

18.29.5 RECENT DEVELOPEMNTS

18.3 IPSEN PHARMA

18.30.1 COMPANY OVERVIEW

18.30.2 REVENUE ANALYSIS

18.30.3 GEOGRAPHIC PRESENCE

18.30.4 PRODUCT PORTFOLIO

18.30.5 RECENT DEVELOPEMNTS

*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST

19 RELATED REPORTS

20 CONCLUSION

21 QUESTIONNAIRE

22 ABOUT DATA BRIDGE MARKET RESEARCH